Pharmacology Finals Review Questions
and Answers Rated 100% Correct
Comprehensive Final Exam Review
75 Questions with Complete Rationales
Aligned with 2026|2027 NCSBN Test Plan
AACN Essentials | QSEN Competencies | Current Pharmacopeia Standards
Department of Nursing Education
April 2026
,Abstract
This comprehensive review document presents 75 carefully constructed pharmacology
examination questions designed for nursing students preparing for the NURS 1140
Pharmacology Final Examination. The questions are systematically organized across
five major content domains: pharmacokinetics, pharmacodynamics, and medication
safety principles; autonomic nervous system, central nervous system, and psychotropic
medications; cardiovascular, renal, and respiratory pharmacotherapy; anti-infectives,
immunizations, and hematologic agents; and endocrine, gastrointestinal, pain
management, and special population considerations. Each question is aligned with the
2026-2027 NCSBN Test Plan, AACN Essentials, QSEN Competencies, and current
pharmacopeia standards. Cognitive levels are distributed as follows: 30% recall, 50%
application, and 20% analysis, reflecting NCLEX-RN Next Generation clinical
judgment item logic. Approximately 75% of questions are scenario-based clinical
vignettes spanning medical-surgical, pediatric, obstetric, and psychiatric nursing
contexts. All questions include detailed rationales that link pharmacological principles
to nursing interventions, promoting deep learning and clinical reasoning competency
development.
Keywords: Pharmacology, NCLEX-RN, Medication Safety, Pharmacokinetics,
Nursing Education, Clinical Judgment, Drug Classification, Patient Safety,
Pharmacotherapy, Nursing Process
Table of Contents
Introduction 4
Section 1: Pharmacokinetics, Pharmacodynamics & Medication Safety Principles
(Q1-Q15) 4
Section 2: Autonomic Nervous System, CNS & Psychotropic Medications (Q16-Q30) 9
Section 3: Cardiovascular, Renal & Respiratory Pharmacotherapy (Q31-Q45) 14
, Section 4: Anti-infectives, Immunizations & Hematologic Agents (Q46-Q60) 19
Section 5: Endocrine, GI, Pain Management & Special Populations (Q61-Q75) 24
References 29